Phase II Study of QL1706 Combined With Paclitaxel and Bevacizumab for Second-Line Immune Rechallenge in Gastric Cancer
Phase II Study of QL1706 Combined With Paclitaxel and Bevacizumab for Second-Line Immune Rechallenge in Gastric Cancer
Not yet recruiting · NCT07045805 · Registry updated 2025-07-01Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Phase II Study of QL1706 Combined With Paclitaxel and Bevacizumab for Second-Line Immune Rechallenge in Gastric Cancer | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, digestive system disorder, digestive system neoplasm, gastric neoplasm, neoplasm, stomach disorder | Not yet recruiting | Phase 2 | 2025-07-01 | NCT07045805 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | 164 |
0 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| No products are listed yet. | |||